Evidence map›Paper›PMID 28774338›Full record

Trial reportCancer imaging : the official publication of the International Cancer Imaging Society2017

Ronald L Korn, Daniel D Von Hoff, Mitesh J Borad, Markus F Renschler, Desmond McGovern, R Curtis Bay, Ramesh K Ramanathan

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer imaging : the official publication of the International Cancer Imaging Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00398086 (A Phase I Trial of Gemcitabine), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00398086 phase1 / phase2completednot on this map

A Phase I Trial of Gemcitabine (Gemzar) Plus ABI-007 (ABRAXANE) In Patients With Advanced Metastatic Pancreatic Cancer

TypeinterventionalSponsorCelgeneRan2006 to 2010Enrolled67ConditionsMetastatic Pancreatic CancerArmsGemcitabine, Albumin-bound paclitaxel
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Clinical Impact ofDiagnostics (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ronald L KornImaging Endpoints Core Lab, 9700 N 91st St, B-200, Scottsdale, AZ, 85258, USA. rkorn@imagingendpoints.com.
Daniel D Von HoffTranslational Genomics Research Institute and HonorHealth, 445 North Fifth St, Suite 600, Phoenix, AZ, 85004, USA.
Mitesh J BoradMayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA.
Markus F RenschlerCelgene Corporation, 86 Morris Ave, Summit, NJ, 07901, USA.
Desmond McGovernCelgene Corporation, 86 Morris Ave, Summit, NJ, 07901, USA.
R Curtis BayDepartment of Interdisciplinary Health Sciences, A. T. Still University, 5850 E Still Circle, Mesa, AZ 85206, USA.
Ramesh K RamanathanMayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA.
Mayo Clinic in Arizona · USA.T. Still University · USCore Laboratories (United States) · USTranslational Genomics Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPositron emission tomography (PET) is poised to become a useful imaging modality in staging and evaluating therapeutic responses in patients with metastatic pancreatic cancer (mPC). This analysis from a phase 1/2 study examined the utility of early PET imaging in patients with mPC treated with nab-paclitaxel plus gemcitabine.

methodsTumors were measured by [

resultsFifty-two patients had baseline and ≥1 follow-up PET scan. The median maximum standardized uptake values per pancreatic lesion in the nab-paclitaxel 100 mg/m

conclusionsThe majority of primary pancreatic tumors and their metastases were PET avid, and PET effectively measured changes in tumor metabolic activity at 6 and 12 weeks. These results support the antitumor activity of nab-paclitaxel 125 mg/m

trial registrationNCT00398086.

Indexed as

Positron Emission Tomography Computed TomographyAdenocarcinomaAdultAgedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineFemaleFluorodeoxyglucose F18GemcitabineHumansMaleMiddle AgedPaclitaxelPancreatic NeoplasmsRadiopharmaceuticals130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineFluorodeoxyglucose F18GemcitabinePaclitaxelRadiopharmaceuticalsGemcitabinenab-PaclitaxelPancreatic cancerPhase 1/2 clinical trialPositron emission tomography

Identifiers

PMID28774338
PMCPMC5543580
OpenAlexW2744932479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.